$NBIX · NEUROCRINE BIOSCIENCES INC SEC Filings
Position Tracker tracks 2 SEC EDGAR filings for NEUROCRINE BIOSCIENCES INC ($NBIX) from November 2, 2026 through November 2, 2026, including 0 Form 10-K annual reports, 1 Form 10-Q quarterly earnings reports, 1 Form 8-K current event disclosures, and 0 Form 4 insider equity transactions. Select any filing below to read the full AI summary, key financial takeaways, and original SEC.gov document.
$NBIX 10-Q — NEUROCRINE BIOSCIENCES INC
Neurocrine is transitioning from an INGREZZA-dependent story to a three-product rare-disease powerhouse, with CRENESSITY and VYKAT XR now contributing 28% of Q3 net product sales.
$NBIX 8-K — NEUROCRINE BIOSCIENCES INC
Neurocrine crossed $1B in quarterly net product sales for the first time, raised INGREZZA guidance, and now has three growing commercial franchises — a pivotal scale milestone f…